Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027497 (
nausea
)
23,468
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We investigated the effect of 5-hydroxytryptamine 3A and 3B receptor (
HTR3A
and HTR3B) gene polymorphisms on
nausea
induced by paroxetine in Japanese psychiatric patients. Blood samples were collected from 78 individuals after at least 2 weeks treatment with the same daily dose of paroxetine. The patients visited every 2 weeks and the paroxetine dose was changed in response to their clinical symptoms.
Nausea
was assessed at each visit. The Tyr129Ser polymorphism of the HTR3B gene had a significant effect on the incidence of
nausea
(P=0.038). Logistic regression analysis also showed that patients with the Tyr/Tyr genotype had a 3.95-fold (P=0.048) higher risk of developing
nausea
than patients with the Ser allele.
HTR3A
gene polymorphisms and the CYP2D6 gene polymorphisms had no significant effect on the incidence of
nausea
. The mean score of
nausea
severity was corrected by the Bonferroni test. HTR3B gene polymorphisms are significant predictors of paroxetine-induced
nausea
.
...
PMID:The effect of 5-hydroxytryptamine 3A and 3B receptor genes on nausea induced by paroxetine. 1653 7
In this study, we tested the influence of the serotonin type 2A, 3A and 3B receptor genes (HTR2A,
HTR3A
, HTR3B) in addition to a polymorphism in the promoter region of the serotonin transporter (SERTPR), and investigated the different characteristics of clinical responses to paroxetine and fluvoxamine. A total of 100 Japanese patients affected by major recurrent depression were enrolled in a randomized 6-week study. The clinical response was evaluated using the Hamilton Rating Scale for Depression (HAM-D), and adverse drug reactions were assessed at each visit. Patients with the l allele of SERTPR showed a better response to SSRIs than s/s genotype carriers (p = 0.015-0.042), more significantly to fluvoxamine. The -1438G/G genotype of HTR2A was associated with a good response to SSRIs (p = 0.010-0.039), especially to fluvoxamine, and significantly with severe
nausea
in paroxetine-treated patients (p = 0.013). The 178C/C genotype of the
HTR3A
was associated with an antidepressant response (p = 0.022-0.042), and more significantly in paroxetine-treated patients (p = 0.002-0.042). These effects were independent of one another. We replicated the finding that the SERPTR polymorphism was associated with a response to SSRIs. We additionally found that HTR2A and
HTR3A
polymorphisms are associated with the efficacy, and the HTR2A polymorphism is also associated with adverse drug reactions. Furthermore, the effects of these polymorphisms varied from one SSRI to another and thus may depend on the characteristics of each SSRI.
...
PMID:Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed Japanese patients. 1687 5